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Abstract
Susceptibility to invasive pneumococcal disease (IPD) correlates with age, younger children being the group with the highest burden of
disease. The relevance of the innate immune response and particularly the role of mannose-binding lectin (MBL) in combating IPD is not well
known. This is a 2-year prospective study (February 2011 to March 2013) including patients with IPD who attended two hospitals from
Catalonia, Spain. Variables including attack rate of pneumococcal serotype (high or low invasive potential serotypes) and genotypes
associated with low serum MBL levels were recorded. One hundred and forty-seven patients were included in the study. One hundred and
two (69.4%) patients were children or adolescents <18 years and 45 (30.6%) were adults. Overall, low-MBL genotypes (O/O; XA/O) were
detected in 23 (15.6%) patients. Children <2 years showed a higher frequency of low-MBL genotypes compared with other patients (31.0%
vs. 11.9%; p = 0.031). Further sub-analysis revealed a higher proportion of low-MBL genotypes in children <2 years with IPD caused by
opportunistic or low-attack-rate serotypes when compared with older patients (46.2% vs. 13.2%; p = 0.02). However, no statistically
signiﬁcant differences between the two groups were observed when including patients infected with invasive or high-attack-rate serotypes
(18.8% vs. 10.0%; p = 0.59). Our data suggest that young children with a genetically determined low-MBL production are at a higher risk of
developing IPD, particularly that caused by opportunistic or low-attack-rate pneumococcal serotypes.
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Introduction
Invasive pneumococcal disease (IPD) is a serious health
problem in children and adults, and causes almost one million
childhood deaths worldwide every year [1]. Streptococcus
pneumoniae usually colonizes the nasopharynx of healthy
children but is less frequently found as a colonizer in adults. It
is estimated that most children are colonized by pneumococcus
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at least once during the ﬁrst 2 years of life and nasopharyn-
geal colonization is the ﬁrst step towards development of
mucosal and invasive diseases [2]. Further spread of pneumo-
coccus to the bloodstream and other normally sterile sites
occurs less often. However, young children, young adults with
immunosuppressive and chronic conditions and older adults
are at higher risk of IPD. The complex interaction between
impaired host factors and the presence of virulence determi-
nants of the pneumococcus may be responsible for developing
IPD [2].
The main virulence factor for pneumococcus is the
polysaccharide capsule, with more than 94 serotypes that
cause varying rates of carriage and IPD. Some of these
serotypes have ‘low attack rate’ and are frequently detected in
carriers. These so-called ‘opportunistic serotypes’ are more
prevalent in children <2 years old, elderly people and patients
with co-morbidities [3]. In contrast, serotypes with a ‘high
attack rate’, also called ‘high-invasive potential serotypes’, are
seldom detected in carriers and often cause IPD, particularly in
older children and adults without co-morbidities [4,5].
Intriguingly, serotypes with a high attack rate, such as
serotypes 1, 5 or 7F, have been associated with a less
complicated course of disease and lower mortality rates than
opportunistic serotypes [6,7],whereas serotypes with a low
attack rate have been related to high mortality and more
serious clinical manifestations, such as meningitis and sepsis
[8].
Mannose-binding lectin (MBL) is a serum protein of the
innate immune system, which recognizes pathogen structures,
mainly of a carbohydrate nature. It can then promote
opsonophagocytosis of a wide range of microorganisms and
subsequent antibody-independent complement activation
[9,10]. It is considered a pre-antibody that has a relevant
defensive role in the ﬁrst period of life, when an immature
adaptive immune system still exists. The serum levels of MBL
are genetically determined as a consequence of single nucle-
otide polymorphisms (SNPs) embedded into the promoter and
the exon 1 of the human MBL2 gene [11]. Homo- and
heterozygous combinations of those SNPs give rise to different
genotypes responsible for high (A/A, XA/A), intermediate (O/
A, XA/XA) or low (O/O, XA/O) serum MBL levels [12].
Previous reports indicate that genetically-determined MBL
deﬁciency is relatively frequent in all human populations
analyzed (ranging from <15% in Caucasian populations to 20%
in sub-Saharan African populations) [13,14]. This deﬁciency has
been linked to increased susceptibility to infectious diseases,
including those caused by pneumococcus [15]. Nonetheless,
this hypothesis remains controversial because some studies
have not observed a signiﬁcant association of MBL deﬁciency
with the development of IPD [16].
The aim of this study was to evaluate the prevalence of
genotypes responsible for low serum MBL levels in patients
with IPD according to age group and serotype attack rate
characteristics. This information could be useful for designing
strategies for prevention and personalized treatment of
patients based on previous analysis of host–pathogen interac-
tions.
Patients and Methods
Participant recruitment
This is a prospective study that includes all patients with IPD
who attended two medical centres (Hospital Sant Joan de Deu
and Hospital de Mataro) from 1 February 2011 to 1 March
2013. The Hospital Sant Joan de Deu (HSJD) is a 360-bed
referral paediatric centre located in the metropolitan area of
Barcelona, which annually captures around 17% of all hospi-
talizations (c. 200 000 children) from the population <18 years
in Catalonia (Spain). The Hospital de Mataro (HM) is a public
general hospital that covers a catchment area of 400 000
inhabitants from the Catalonian area of Maresme.
Only one episode (the ﬁrst) per patient was included in the
study sample. Patients with functional deﬁcit of classical or
alternative pathways of complement activation were excluded
from the study, as well as patients with immunocompromised
conditions (HIV infection, immunoglobulin deﬁcit), cystic
ﬁbrosis, bronchiectasis or cerebrospinal leak.
Demographic and clinical variables including age, sex,
ethnicity, IPD risk factors, pneumococcal vaccination status,
pneumococcal serotypes and their invasiveness potential, MBL
production levels, clinical diagnosis, course of disease, length of
hospital stay (LOS) and admission to intensive care unit (ICU)
were registered for each episode.
The study was performed following the guidelines of the
Ethics Committees of Hospital Sant Joan de Deu and Hospital
de Mataro.
Microbiological and immunological methods
Invasive pneumococcal disease was deﬁned as the presence of
clinical ﬁndings of infection (which were used for classiﬁcation
of disease) together with isolation of Streptococcus pneumoniae
and/or DNA detection of the pneumolysin (ply) gene and an
additional capsular gene of S. pneumoniae by real-time PCR in
plasma, cerebrospinal ﬂuid or any other sterile ﬂuid. All
pneumococcal isolates were identiﬁed by standard microbio-
logical methods. DNA detection of the pneumolysin (ply) gene
by real-time PCR in normal sterile ﬂuids was performed
according to a previously reported assay [17]. Serotyping of
strains isolated by culture was carried out by a molecular
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technique based on automated ﬂuorescent fragment analysis,
which allows differentiation of 40 serotypes [18]. Detection of
pneumococcal serotypes in culture-negative clinical samples
was performed by multiplex real-time PCR methodology [19].
Both molecular techniques were performed at the Molecular
Microbiology Department of Hospital Sant Joan de Deu, which
operates as the regional support laboratory for pneumococcus
surveillance in Catalonia. Quellung reaction performed at the
National Center for Microbiology (Majadahonda, Madrid) was
used to complete serotyping in strains isolated by culture.
Serotypes were classiﬁed according to the studies of
Brueggemann [4] and Sleeman [5]: 1, 4, 5, 7F, 9V, 14, 18C
and 19A were considered to have a ‘high attack rate’ whereas
the remainder were considered to be non-invasive or oppor-
tunistic serotypes with a ‘low attack rate’.
MBL2 polymorphism analysis
DNA extraction, ampliﬁcation and genotyping of MBL2 were
carried out as previously described [20]. Six single nucleotide
polymorphisms (SNPs) in the 50-ﬂanking/promoter region
(550 G/C 221 C/G, 4 C/T) and exon 1 (codon 52 CGT/
TGT, codon 54 GGC/GAC and codon 57 GGA/GAA) of the
MBL2 gene were analysed using a polymerase chain reaction
(PCR) and sequence-based typing (SBT) technique. The SNPs
at codons 52, 54 and 57 are named D, B and C variants,
respectively, and are major determinants of serum MBL levels
[10,11]. These variants are collectively named O, while A
indicates the wild-type variant. The SNPs at positions 551
(H/L), 221 (X/L) and +4 (P/Q) also inﬂuence serum MBL
levels in individuals with the wild-type A variant [16].
However, the functional effects of H/L and P/Q SNPs appear
to be minor compared with L/X, X being the allele associated
with lower MBL expression. Accordingly, haplotype combina-
tions O/O and O/XA were considered as low-MBL producing
genotypes, O/A and XA/XA as intermediate-producing, and A/
A and XA/A as high-producing genotypes.
Statistical analysis
Statistical analyses were performed using Statistical Package
for Social Sciences software (SPSS Statistics for Windows,
version 20.0, IBM Corp., Chicago, IL, USA). Continuous
variables were summarized as means and standard deviations
(SDs) or as medians and interquartile ranges (IQR, 25th to
75th percentile) according to their homogeneity. Categorical
variables were compared with the chi-squared test or the
Fisher’s exact test (two-tailed) when appropriate. Continuous
variables were compared with the Mann–Whitney U-test or
Student t-test according to their homogeneity. Signiﬁcance
was set at a two-sided p-value of <0.05 for all statistical
analyses. p-values were corrected according to the Holm
method for multiple comparisons. An eligible population of
170 subjects was expected to be collected in the two
hospitals during the study period, according to incidence
rates of previous years. Based on results described in
previous studies, proportions of low vs. medium-high MBL
levels were assumed to be 15% and 85%, respectively, while
proportions of IPD caused by opportunistic serotypes vs.
high-attack serotypes were assumed to be 50% and 50%. The
conﬁdence level was set at 95% (two-tailed), precision of
conﬁdence interval at 3%, and rate of subjects not meeting
inclusion criteria at 10%. It was calculated that the minimum
sample size to be recruited for the study needed to include
164 subjects from the eligible population.
Results
A total of 203 IPD episodes among 200 patients were
recorded in the two institutions. Of these, 36 patients did
not give consent to participate in the study (18%) and 17 did
not meet inclusion criteria (two patients with cerebrospinal
leak, three patients with HIV infection, and 12 patients with
immunosuppression treatment). Thus, the ﬁnal study sample
comprised 147 patients with IPD.
Eighty-ﬁve patients (57.8%) were recruited at Hospital Sant
Joan de Deu and 62 (42.2%) at Hospital de Mataro. The
predominant gender was male (85 patients; 57.8%) and the
predominant ethnic group was Caucasian (n = 110; 74.8%).
Children or adolescents <18 years of age were also the
predominant age group (n = 102; 69.4%). The median age of
paediatric patients was 2.9 years (IQR, 1.7–5.3 years) while
the median age of adults was 54.0 years (IQR, 47.1–
77.6 years). Pneumonia was the most frequent clinical diagno-
sis (n = 125; 85.0%); 66 subjects had complicated pneumonia.
This was followed by meningitis (n = 12; 8.2%) and bactera-
emia/sepsis (n = 10; 6.8%). One hundred and thirty-seven
(93.2%) patients required hospitalization, with a median LOS of
9.0 days (IQR, 6.0–14.0), and 25 (17.0%) patients required
admission to the Paediatric Intensive Care Unit (PICU). Only
45 (30.6%) patients had previously been vaccinated; 15 (10.2%)
suffered sequelae and three adults died.
Sixty-ﬁve (44.2%) episodes were conﬁrmed only by PCR, 61
(41.5%) by culture and 21 (14.3%) by both PCR and culture.
Overall, the rank order of serotypes was serotype 1 (n = 36;
24.5%), serotype 3 (n = 22; 15.0%), serotype 19A (n = 11;
7.5%) and serotype 7F (n = 10; 6.8%). Serotypes included in
the 13-valent pneumococcal conjugate vaccine were found in
74 (72.5%) of 102 children and adolescents younger than
18 years and in 21 (46.7%) of 45 adults. Serotypes with a high
attack rate were identiﬁed in 66 (44.9%) episodes.
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Table 1 shows the MBL2 genotype frequencies found in this
study. A genotype associated with low production of MBL (O/
O; XA/O) was detected in 23 (15.6%) patients, while
genotypes associated with intermediate and high MBL pro-
duction were detected in 45 (30.6%) and 79 (53.7%) patients,
respectively. Table 2 shows demographic, clinical, microbio-
logical and genotypical variables of patients according to age
group.
Low-MBL genotypes were not found to be signiﬁcantly
associated with the variables of sex, ethnicity, serotype
invasiveness and PICU admission. A higher proportion of
low-MBL genotypes was observed among patients with
meningitis in comparison with other clinical presentations
(33.3% vs. 14.1%) but this tendency did not reach a statistically
signiﬁcant value (p = 0.191). Children younger than 2 years
showed a signiﬁcantly higher frequency of low-MBL genotypes
compared with the other patients (31.0% vs. 11.9%;
p = 0.031). Nevertheless, correction for multiple comparisons
did not conﬁrm signiﬁcance of this association (corrected
p-value = 0.186). Data regarding associations between vari-
ables are presented in Table 3.
A sub-analysis of patients by age group (considering children
<2 years old vs. other patients) revealed considerable pro-
portions of carriers of low-MBL genotypes among children
<2 years old with IPD caused by opportunistic serotypes
(46.2%), diagnosed with meningitis (42.9%), admitted to the
ICU (40%) and of Caucasian ethnicity (36.8%). When com-
paring the frequency of low-MBL genotypes in these younger
children and in other patients, ratios of proportions (R)
between the two age groups were found to be statistically
signiﬁcant in Caucasian patients (p = 0.013) and in patients
with IPD caused by opportunistic serotypes (p = 0.020). These
results are recorded in Table 4.
Discussion
Susceptibility to IPD has been reported to be clearly related
to age, and younger children are the group with the highest
burden of disease [1,3]. The importance of the innate
immune response in combating infections is well docu-
mented. Contrary to adaptive immunity, which takes days to
generate and expand a speciﬁc humoral and/or cellular
response against the pathogen, the innate response acts
immediately (within minutes or hours). This innate immune
system acts as a ﬁrst-line defensive barrier, which is critical to
contain the passage of nasopharyngeal colonizers to normally
sterile sites until lymphocytes and speciﬁc antibodies take
action [21]. It is also well known that the type and magnitude
of the adaptive immune response vary with age, developing
from immaturity at birth to maturity after the ﬁrst 2 years of
life, although it takes even longer for the adaptive immune
system to fully develop. Therefore, in younger children the
ﬁght against infections mainly relies on the innate immune
system.
An international study has analysed the association between
mortality, clinical manifestations and recovery of invasive
serotypes vs. non-invasive serotypes, and has shown that host
factors are better predictors of associated morbidity and
mortality of IPD than serotype invasiveness [8]. That is,
whether an opportunistic serotype will cause disease and/or
determine a worse evolution is more strongly related to a
deﬁcient host immunological response than to microbiological
factors.
In the present study, we found a signiﬁcantly high propor-
tion of genotypes associated with low MBL production among
children younger than 2 years with IPD. Moreover, the
frequency of low-MBL genotypes was observed to be
especially high (46.2%) in younger children with IPD caused
by opportunistic serotypes. These data suggest that pneumo-
coccal nasopharyngeal colonizers have more opportunities to
cause invasive disease in young children with a geneti-
cally-determined low MBL production, which is a crucial
factor in the innate immune response. Interestingly, when rates
of low-MBL genotypes among patients with IPD caused by
serotypes with high invasiveness (high-attack-rate serotypes)
were analyzed, we did not ﬁnd a signiﬁcantly high proportion
of low-MBL genotypes either in young children aged <2 years
or in other patients. Serotypes with a high attack rate are bad
colonizers, and different studies have shown that they have
important virulence factors associated with the production of
pleuropneumonia or other clinical manifestations of IPD [22].
These data suggest that in the case of high-attack-rate
serotypes, microbiological factors may proportionally have
TABLE 1. MBL2 genotype frequencies in 147 patients with
invasive pneumococcal disease
MBL genotype
group Frequencies %
YA/YA 42 28.6
YA/XA 37 25.2
XA/XA 6 4.1
Overall A/A 85
YA/YB 21 14.3
XA/YB 6 4.1
YA/YC 7 4.8
XA/YC 2 1.4
YA/YD 11 7.5
XA/YD 2 1.4
Overall A/O 49
YB/YB 4 2.6
YB/YC 3 2.0
YB/YD 4 2.6
YC/YC 1 0.7
YC/YD 0 0
YD/YD 1 0.7
Overall O/O 13
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more weight in causing disease, regardless of the quality of the
immune response.
Our data about the implication of MBL in the development of
IPD in young children are novel but in agreement with studies
performed in mice about the role of MBL in susceptibility to
pneumococcal infection [23]. In addition, data also exist
documenting the implication of MBL deﬁciency in other
paediatric infectious diseases. A recent systematic review has
TABLE 2. Demographic, clinical, microbiological and genotypical characteristics of patients according to age group
Characteristics <2 years ≥2 and <5 years ≥5 and <65 years ≥65 years Total
Subjects 29 (19.7) 45 (30.6) 56 (38.1) 17 (11.6) 147
Sex
Male 14 (48.3) 24 (53.3) 38 (67.9) 9 (52.9) 85 (57.8)
Female 15 (51.7) 21 (46.7) 18 (32.1) 8 (47.1) 62 (42.2)
Ethnicity
Caucasian 19 (65.5) 31 (68.9) 45 (80.4) 15 (88.2) 110 (74.8)
Non-Caucasian 10 (34.5) 14 (31.1) 11 (19.6) 2 (11.8) 37 (15.2)
Clinical manifestation
Pneumonia 18 (62.0) 39 (86.7) 53 (94.6) 15 (88.2) 125 (85.0)
Meningitis 7 (24.1) 2 (4.4) 1 (1.8) 2 (11.8) 12 (8.2)
Bacteraemia/sepsis 4 (13.8) 4 (8.9) 2 (3.6) 0 10 (6.8)
ICU admission (n = 137)a
No 18 (64.3) 34 (79.1) 45 (90.0) 15 (93.8) 112 (83.0)
Yes 10 (35.7) 9 (20.9) 5 (10.0) 1 (6.3) 25 (17.0)
Clinical course (n = 129)a
No sequelae 15 (62.5) 33 (86.8) 48 (96.0) 15 (88.2) 111
Sequelae 9 (37.5) 5 (13.2) 1 (2.0) 0 15
Exitus 0 0 1 (2.0) 2 (11.8) 3
IPD risk factor (n = 127)a
No 23 (95.8) 38 (100.0) 39 (81.3) 5 (29.4) 105
Yes 1 (4.2) 0 9 (18.8) 12 (70.6) 22
Vaccine receipt
No 21 (72.4) 26 (57.8) 50 (89.3) 17 (100) 114
PCV7 0 16 (35.6) 6 (10.7) 0 22
PCV10 1 (3.4) 1 (2.2) 0 0 2
PCV13 7 (24.1) 1 (2.2) 0 0 8
PCV7 & PCV13 0 1 (2.2) 0 0 1
Serotype invasiveness
High 16 (55.2) 17 (37.8) 31 (55.4) 2 (11.8) 66 (44.9)
Non-high 13 (44.8) 28 (62.2) 25 (44.6) 15 (88.2) 81 (55.1)
PCV13 serotype
No 7 (24.1) 13 (28.9) 19 (33.9) 13 (76.5) 52
Yes 22 (75.9) 32 (71.1) 37 (66.1) 4 (23.5) 95
MBL levels
High (A/A) 10 (34.5) 22 (48.9) 36 (64.3) 11 (64.7) 79 (53.7)
Medium (XA/XA or A/O) 10 (34.5) 19 (42.2) 12 (21.4) 4 (23.5) 45 (30.7)
Low (X/A or O/O) 9 (31.0) 4 (8.9) 8 (14.3) 2 (11.8) 23 (15.6)
LOS (days) 14 (9.3–17.8) 9 (7.0–11.0) 8.5 (5.0–12.3) 7 (5.0–9.0) 9 (6.0–14.0)
ICU LOS days 2.5 (1.0–18.0) 1.0 (1.0–2.5) 1.0 (1.0–8.0) 0 1.0 (1.0–6.5)
Data are presented as n (%) or median (IQR).
aMissing values.
IPD, invasive pneumococcal disease; LOS, length of stay; ICU, intensive care unit; MBL, mannose-binding lectin; PCV7/PCV10/PCV13, 7-valent/10-valent/13-valent pneumococcal
vaccine.
TABLE 3. Variable frequencies according to MBL level
Variables
Patients with low
MBL level
Patients with medium/
high MBL level p-Value
Corrected
p-value
Age
<2 years old 9 (31.0) 20 (69.0) 0.031 0.186
≥2 years old 14 (11.9) 104 (88.1)
Sex
Male 14 (16.5) 71 (83.5) 0.747 1.000
Female 9 (14.5) 53 (85.5)
Ethnicity
Caucasian 16 (14.5) 94 (85.5) 0.526 1.000
Non-Caucasian 7 (18.9) 30 (81.1)
Clinical manifestation
Meningitis 4 (33.4) 8 (66.7) 0.191 0.955
Pneumonia/bacteraemia/sepsis 19 (14.1) 116 (85.9)
ICU admission (n = 137)a
No 18 (16.1) 94 (83.9) 0.826 1.000
Yes 5 (20.0) 20 (80.0)
Serotype invasiveness
High 8 (12.1) 58 (87.9) 0.290 1.000
Non-high 15 (18.5) 6 (81.5)
Data are presented as n (%).
Signiﬁcant values in bold numbers.
aMissing values.
ICU, intensive care unit; PCV13, 13-valent pneumococcal vaccine.
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reported a probable association between HIV disease progres-
sion and MBL deﬁciency, and this association was especially high
in children <2 years of age [24]. Dommett et al. [25] have
reported the inﬂuence of MBL in the frequency and duration of
infectious complications in children with malignancy. Finally,
Koch et al. [26] report a statistical association of MBL insufﬁ-
ciency with the increase of risk of acute respiratory infection in
children between 6 and 17 months. These results contrast with
those documented in other populations without infectious
diseases. A study performed in a cohort of newborns in the
Netherlands showed that a low-MBL genotype was only
observed in eight of 56 (14.2%) premature newborns and in
two of 11 (18.1%) preterm neonates [27]. Another study
performed in our geographical area reported a similar percent-
age of 15.3% among adults [13].
It was also of interest to ﬁnd out that younger patients with
pneumococcal meningitis showed a high proportion of
low-MBL genotypes (42.9%), even though this proportion did
not reach statistical signiﬁcance when compared with the
proportion of low-MBL genotypes in older patients. These data
are in agreement with a recent study that reports an
association between defective MBL genotypes and an increased
risk of pneumococcal meningitis [28]. The hypothesis that MBL
deﬁciency could be related to a worse clinical evolution should
not be ruled out and deserves further analysis.
The signiﬁcance of MBL binding S. pneumoniae is contro-
versial because studies show low MBL binding to S. pneumo-
niae as well as to other encapsulated bacteria [29]. Therefore,
other mechanisms distinct from complement-mediated opso-
nophagocytosis and bacterial killing of S. pneumoniae by MBL
could be the basis of the clinical association reported here. In
this regard, there is also evidence of direct interaction of MBL
with phagocytic cells to promote phagocytosis and modify
cellular activation [30], as well as increasing evidence in
support of an immunomodulatory effect of MBL [31].
Our study should be interpreted in light of several
limitations. First, although the study sample allowed us to
obtain statistically signiﬁcant results, analysis of more extensive
populations should be undertaken to conﬁrm our results,
particularly in relation to the association between a geneti-
cally-determined MBL deﬁciency and the onset of pneumo-
coccal meningitis. Second, our study does not exclude the
putative contribution of other soluble pattern recognition
innate immune proteins also potentially involved in the defence
of the lungs against S. pneumoniae or other bacteria, such as
surfactant proteins (SP-A and SP-D) [32], ﬁcolins [33],
pentraxins [34] or agglutinin gp-340/DMBT1 [35]. Third, we
did not analyse other factors that may be involved in the step
from colonization to disease and, in particular, the role of
co-infection with respiratory viruses. Viral infection is very
common in young children and it has been suggested that the
acquisition of a virus damages the epithelial mucosa and
promotes the expression of virulence determinants in the
pathogen, which are related to adhesiveness to the mucosa
and bacterial replication [36]. Moreover, the role of MBL in
direct viral neutralization and inhibition of viral spread is well
known [37]. Additional analysis is needed to determine
whether deﬁciencies in innate immunity and co-infection with
respiratory viruses together create the perfect situation for
development of IPD in children.
In conclusion, our ﬁndings suggest an association of
genetically determined low MBL production and IPD in
younger children. Further conﬁrmation of this novel associa-
tion may open a pathway to the practice of personalized
medicine in which paediatricians would not only evaluate the
risk of IPD according to clinical, epidemiological and micro-
biological characteristics of the episode, but also according to
predictive factors derived from the immune characteristics of
the host. Our results also support the need to adopt a more
integrated approach to the diagnosis and treatment of IPD in
TABLE 4. Variable frequencies according to age group and MBL level
Variables
Age group <2 years (n = 29) Age group ≥2 years (n = 118) Patients with low MBL level
Total number
of patients
Patients with
low MBL level
Total number
of patients
Patients with
low MBL level p-Value R (95% CI)
Ethnicity
Caucasian 19 7 (36.8) 91 9 (9.9) 0.013 3.73 (1.58–8.76)
Non-Caucasian 10 2 (20.0) 27 5 (18.5) 1.000 1.08 (0.25–4.70)
Clinical manifestation
Meningitis 7 3 (42.9) 5 1 (20.0) 0.849 2.14 (0.30–15.07)
Others 22 6 (27.3) 113 13 (11.5) 0.121 2.37 (1.01–5.56)
ICU admissiona
No 18 5 (27.8) 94 13 (13.8) 0.263 2.01 (0.82–4.94)
Yes 10 4 (40.0) 15 1 (6.7) 0.128 6.00 (0.78–46.14)
Serotype invasiveness
High 16 3 (18.8) 50 5 (10.0) 0.593 1.88 (0.50–6.99)
Non-high 13 6 (46.2) 68 9 (13.2) 0.020 3.49 (1.50–8.12)
Signiﬁcant values in bold numbers.
aMissing values.
R, ratio of proportions; CI, conﬁdence interval; ICU, intensive care unit; PCV13, 13-valent pneumococcal vaccine.
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young children in order to achieve better clinical outcomes for
this particular group of patients. The challenge of ﬁnding a
vaccine based on preserved pneumococcal proteins protecting
against all serotypes could be the next response in the
prevention of pneumococcal disease.
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